Perrigo Stock To Go Ex-dividend Tomorrow (PRGO)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- The ex-dividend date for Perrigo Company (Nasdaq: PRGO) is tomorrow, August 29, 2012. Owners of shares as of market close today will be eligible for a dividend of 8 cents per share. At a price of $110.08 as of 9:30 a.m. ET, the dividend yield is 0.3%.

The average volume for Perrigo has been 676,800 shares per day over the past 30 days. Perrigo has a market cap of $10.33 billion and is part of the health care sector and drugs industry. Shares are up 13.7% year to date as of the close of trading on Monday.

Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API) worldwide. The company has a P/E ratio of 26.4, above the average drugs industry P/E ratio of 25.9 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Perrigo as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Perrigo Ratings Report.

See our dividend calendar or top-yielding stocks list.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing